Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued to investors on Saturday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

NASDAQ:BLPH opened at $0.04 on Friday. Bellerophon Therapeutics has a 12-month low of $0.03 and a 12-month high of $0.42. The stock’s 50 day simple moving average is $0.04 and its 200-day simple moving average is $0.05. The firm has a market cap of $428,155.00, a P/E ratio of -0.04 and a beta of 0.70.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.